Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
[powerpress]
ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC Audio Podcast
Please feel free to offer comments and raise questions in our
discussion forums.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.